Novartis China President and Managing Director Leo Lee Joins PhRMA China Executive Liaison Group

July 2, 2024  Source: drugdu 124

"/The Pharmaceutical Research and Manufacturers of America (PhRMA) China Office announced that Mr. Leo Lee, President and Managing Director of Novartis China, has joined the PhRMA China Executive Liaison Group.

Mr. Lee, a long-time veteran of the biopharmaceutical industry who has held senior management positions in a number of multinational corporations and has extensive experience in strategy development and implementation, business development and operational management, joins PhRMA's China Executive Liaison Group and expresses its confidence that Mr. Lee will bring invaluable experience to the group, as well as its appreciation to the member companies for their continued support of PhRMA.

Novartis is a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).

About the PhRMA China Executive Liaison Group
The China Executive Liaison Group (CELG) consists of the China General Managers of PhRMA member companies. As an important bridge between PhRMA China Office and member companies in China, the China Executive Liaison Group will continue to provide key insights on China-related issues and guide the China Office in implementing PhRMA's established goals and priorities for the development of China's biopharmaceutical innovation ecosystem.

About Novartis

Novartis is an innovative drug company focused on four core therapeutic areas: cardiovascular, renal and metabolic, immunology, neuroscience and oncology, and five technology platforms: chemotherapy, biologic therapy, gene and cell therapy, radioligand therapy and xRNA therapy.

The Chinese name of Novartis means "Commitment to China", i.e. to improve the health and quality of life of the Chinese people through innovative products and services, which fully reflects Novartis' long-term commitment to China and its people.

Since 1987, more than 100 Novartis innovative drugs and new indications have been approved in China, and in 2023, Novartis' innovative drugs have benefited nearly 73 million Chinese patients.

https://mp.weixin.qq.com/s?__biz=MjM5MjYxMzUxOA==&mid=2652032851&idx=1&sn=780dd1e633f1046190df9818b86cfd72&chksm=bd45fab28a3273a4c988c6cd41a7310e0e9faad9eeee2e8ad7eb7b08156342635e560515b239&mpshare=1&scene=1&srcid=0701JPzySNQHd8oBx0l7UnZJ&sharer_shareinfo=33aa30433bd3c747f9c1fa7b6ad5505c&sharer_shareinfo_first=33aa30433bd3c747f9c1fa7b6ad5505c#rd

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.